BioInformant

Your Global Leader in Stem Cell Market Research

BMS Pays Evotec $6M as Companies Expand iPSC Collaboration

By Leave a Comment

Adding Cell Types Supports Drug Discovery of Disease-Modifying Therapies for Neurodegenerative Diseases and Triggues U.S. $6 M Payment to Evotec 

Hamburg, Germany, January 7, 2020 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.

Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.

This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times. [Read more…]

International Perinatal Stem Cell Society to Host Two Scientific Conferences in 2020

By

Kyle Cetrulo, President
Kyle Cetrulo, President, International Perinatal Stem Cell Society

The International Perinatal Stem Cell Society is a non-profit organization founded on the principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders worldwide.

For many years, the Perinatal Stem Cell Society has been hosting an annual conference featuring the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific programs cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices.

Below, Kyle Cetrulo, President of the International Perinatal Stem Cell Society, explains the future of perinatal stem cell science and the role that the Society’s 2020 Scientific Conferences will play in advancing this mission. [Read more…]

What Is An RMAT? List of RMAT Designations (39)

By

An RMAT is a “Regenerative Medicine Advanced Therapy” designation and this is a list of the 39 publicly announced RMAT Designations to date. At least 5 more have bee approved, as the FDA states it has received 115 requests and issued 44. This means 38% of RMAT requests get approved.

Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.

Recent additions include Adaptimmune Therapeutics T-cell therapy ADP-A2M4 for the treatment of Synovial Sarcoma n December 3, 2019, as well as Bristol-Myers Squibb’s Liso-cel, an autologous anti-CD19 CAR-T cell therapy.

[Read more…]

Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating iPS Cells

By

Lineage Cell and AgeX get issued U.S. Patent that Precedes the first scientific publication of Shinya Yamanaka.

CARLSBAD, Calif., Dec 10, 2019 — Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells” covering what is commonly designated “induced Pluripotent Stem (iPS) cells.” The issued claims include methods to manufacture pluripotent cells capable of becoming any cell in the body.

The patent has an early priority date, having been filed before the first scientific publication of Shinya Yamanaka, for which he won the Nobel Prize for Physiology or Medicine in 2012. [Read more…]

BioInformant's World-Class Clients